Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells

Oncology Reports

Volumn 14, Issue 4, 2005, Pages 993-997

  Nomura, Takeo ^a,b   Yamasaki, Mutsushi ^a   Nomura, Yoshio ^a   Mimata, Hiromitsu ^a  

^a OITA UNIVERSITY   (Japan)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Inhibitors of apoptosis proteins; LNCaP

Indexed keywords

2 (4 IODOPHENYL) 3 (4 NITROPHENYL) 5 (2,4 DISULFOPHENYL) 2H TETRAZOLIUM; 2-(4-IODOPHENYL)-3-(4-NITROPHENYL)-5-(2,4-DISULFOPHENYL)-2H-TETRAZOLIUM; BIRC2 PROTEIN, HUMAN; BIRC3 PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; BISBENZIMIDE; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INHIBITOR OF APOPTOSIS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PACLITAXEL; TAXOID; TETRAZOLIUM; TUMOR PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; DOSE RESPONSE; DRUG RESISTANCE; HUMAN; IMMUNOBLOTTING; MALE; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; PHENOTYPE; PROSTATE TUMOR; TIME; TUMOR CELL LINE;

APOPTOSIS; BISBENZIMIDE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FLUOROURACIL; HUMANS; IMMUNOBLOTTING; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEURONAL APOPTOSIS-INHIBITORY PROTEIN; PACLITAXEL; PHENOTYPE; PROSTATIC NEOPLASMS; TAXOIDS; TETRAZOLIUM SALTS; TIME FACTORS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 33644823859     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.4.993     Document Type: Article

References (30)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Michael JT: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003. (Pubitemid 36163619)
2. OH WK: Secondary hormonal therapies in the treatment of prostate cancer. Urology 60 (Suppl 1): 87-92, 2002.
3. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43: 79-86, 2002.
4. Taniguchi K, Wada M, Kohno K, et al: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56: 4124-4129, 1996. (Pubitemid 26305002)
5. Komatsu M, Sumizawa T, Mutoh M, et al: Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60: 1312-1316, 2000. (Pubitemid 30152000)
6. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC and Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
7. Kelly SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815, 1998.
8. Parker RJ, Eastman A, Bostick-Bruton F and Reed E: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 772-777, 1991.
9. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998.
10. Henkels KM and Turchi JJ: Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 59: 3077-3083, 1999. (Pubitemid 29316005)
11. Li J, Feng Q, Kim JM, et al: Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142: 370-380, 2001. (Pubitemid 32183698)
12. Nomura T, Mimata H, Yamasaki M and Nomura Y: Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells. Urol Oncol 22: 453-460, 2004. (Pubitemid 43193732)
13. Deveraux QL, Takahashi R, Salvesen GS and Reed JC: X-linked IAP is a direct inhibitor of cell death proteases. Nature 388: 300-304, 1997. (Pubitemid 27317977)
14. Deveraux QL, Roy N, Stennicke HR, et al: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223, 1998. (Pubitemid 28171907)
15. Roy N, Deveraux QL, Takahashi R, Salvesen GS and Reed JC: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16: 6914-6925, 1997. (Pubitemid 27520792)
16. Tamm I, Wang Y, Sausville E, et al: IAP-family protein surviving inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998. (Pubitemid 28551107)
17. Chen Z, Naito M, Hori S, Mashima T, Yamori T and Tsuruo T: A human IAP family gene Apollon expressed in human brain cancer cells. Biochem Biophys Res Commun 264: 847-854, 2001.
18. Kasof GM and Gomes BC: Livin, a novel inhibitor of apoptosis proteins (IAP) family member. J Biol Chem 276: 3238-3246, 2001.
19. Richter BWM, Mir SS, Eiben LJ, et al: Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol 21: 4292-4301, 2001. (Pubitemid 32565310)
20. Krajewska M, Krajewski S, Banares S, et al: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9: 4914-4925, 2003. (Pubitemid 37323298)
21. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
22. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979. (Pubitemid 9256559)
23. Kyprianou N, King ED, Bradbury D and Rhee JG: Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70: 341-348, 1997. (Pubitemid 27099605)
24. Litman T, Druley TE, Stein WD and Bates SE: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959, 2001. (Pubitemid 32652819)
25. Notarbartolo M, Cervello M, Poma P, Dusonchet L, Meli M and D'Alessandro N: Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep 11: 133-136, 2004.
26. Xu H, Choi SM, An CS, et al: Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun 328: 618-622, 2005. (Pubitemid 40208356)
27. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
28. Dole M, Nunez G, Merchant AK, et al: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54: 3253-3259, 1994. (Pubitemid 24208938)
29. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S and Shiina H: Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171: 1855-1860, 2004. (Pubitemid 38501022)
30. Zhang M, Latham DE, Delaney MA and Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24: 2474-2482, 2005. (Pubitemid 40593038)